NCT03004833View on ClinicalTrials.gov

Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

February 21, 2017

Primary Completion Date

August 22, 2022

Study Completion Date

August 22, 2022

Conditions
Classical Hodgkin Lymphoma
Interventions
DRUG

Nivolumab

Infusion of Nivolumab

DRUG

Adriamycin

Infusion of Adriamycin

DRUG

Vinblastine

Infusion of Vinblastine

DRUG

Dacarbazine

Infusion of Dacarbazine

Trial Locations (1)

Unknown

University Hospital of Cologne, Cologne

All Listed Sponsors
lead

University of Cologne

OTHER

NCT03004833 - Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter